A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Public ClinicalTrials.gov record NCT01686555. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the safety, tolerability and pharmacokinetics of ABT-199 in female subjects with Systemic Lupus Erythematosus.
Study identification
- NCT ID
- NCT01686555
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 97 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2012
- Primary completion
- May 31, 2015
- Completion
- May 31, 2015
- Last update posted
- Nov 19, 2017
2012 – 2015
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 89694 | Clearwater | Florida | 33765 | — |
| Site Reference ID/Investigator# 131720 | DeBary | Florida | 32713 | — |
| Site Reference ID/Investigator# 118637 | Miami | Florida | 33136 | — |
| Site Reference ID/Investigator# 124116 | Miami Lakes | Florida | 33016 | — |
| Site Reference ID/Investigator# 89693 | Orlando | Florida | 32806 | — |
| Site Reference ID/Investigator# 78256 | Overland Park | Kansas | 66212 | — |
| Site Reference ID/Investigator# 129826 | Rochester | Minnesota | 55905 | — |
| Site Reference ID/Investigator# 89773 | Manhasset | New York | 11030 | — |
| Site Reference ID/Investigator# 78254 | Duncansville | Pennsylvania | 16635 | — |
| Site Reference ID/Investigator# 123335 | Dallas | Texas | 75231 | — |
| Site Reference ID/Investigator# 78253 | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01686555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2017 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01686555 live on ClinicalTrials.gov.